Start
Entdecken
nav.journalClub
Trends
Mehr
synapse
⌘+K
Sprache
Deutsch
Deutsch
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a phase 2a trial | Synapse
March 3, 2026
Open Access
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a phase 2a trial
DD
Dimitri Henriques Daldegan-Bueno
CD
C Donegan
RS
Rachael L. Sumner
University of Auckland
See all
Key Points
Mood improvement was observed with LSD microdosing, indicating a potential new treatment option.
Participants experienced significant changes in pharmacokinetic profiles associated with mood enhancements.
This observational analysis included a phase 2a trial design with specific focus on mood and biomarkers.
Further exploration is needed to assess the long-term effects and stability of these improvements.
Read Full Paper
externally
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Cite This Study
Copy
Daldegan-Bueno et al. (Sun,) studied this question.
synapsesocial.com/papers/69a761f4c6e9836116a300b7
https://doi.org/https://doi.org/10.1016/j.pnpbp.2026.111645